Answers are grounded in this paper and cite their sources.
The development of protein-based systems capable of delivering bioactive compounds remains an important challenge in pharmaceutical formulation science. In this study, β-lactoglobulin (βLG) was investigated as a biocompatible nanocarrier for norjuziphine, 1-[(4-hydroxyphenyl)methyl]-7-methoxy-1,2,3,4-tetrahydroisoquinolin-8-ol. The binding mechanism, protein structural changes, physicochemical characteristics, drug-release behavior, and biological performance of norjuziphine–βLG nanocomplexes were comprehensively characterized. Fluorescence quenching studies demonstrated spontaneous static complex formation with binding constants in the range of 10 5 –10 6 L mol −1 . Spectroscopic, calorimetric, and computational analyses consistently showed ligand-induced conformational remodeling and stabilization of βLG. The resulting nanocomplexes exhibited spherical morphology with a mean hydrodynamic diameter of 190.1 ± 10.34 nm and an encapsulation efficiency of approximately 79.0%. In vitro release studies demonstrated controlled drug release behavior with moderate pH dependence. Nanoencapsulation increased intracellular norjuziphine accumulation by approximately 2.3-fold relative to free norjuziphine and was associated with enhanced antiproliferative activity in human hepatocellular carcinoma (HCC) cells, a reduced IC 50 value (15.3 ± 2.33 μM), and significant regulation of Bax, Bcl-2, and Caspase-3 expression. Collectively, these findings establish a mechanistic relationship between hydrophobic interaction-driven complexation, protein conformational remodeling, and delivery performance, highlighting β-lactoglobulin as a promising protein-based carrier for improving the delivery of bioactive compounds.
No takes yet. Share an insight, caveat, or question.
Cen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: